Group 1 - The company received a notice regarding the extension of the shareholding increase plan due to various factors affecting the effective time for implementation [1] - The shareholding increase plan will be extended by 4 months until May 31, 2025, while other contents of the original plan remain unchanged [1] - As of the announcement date, the total shares increased by Mr. Xiao Zhihua and Ms. Ni Liangping were 147,995 shares and 11,111 shares respectively, representing 0.1303% and 0.0098% of the total share capital [1] Group 2 - In 2024, the revenue composition of Aopumai was as follows: 82.16% from culture medium business, 17.68% from CDMO services, and 0.16% from leasing income [2] Group 3 - Aopumai announced a plan for its controlling shareholder and senior management to increase their shareholding by at least RMB 6 million within 12 months starting from January 31, 2024 [4]

证券代码：688293 证券简称：奥浦迈 公告编号：2025-042 上海奥浦迈生物科技股份有限公司 关于控股股东兼董事长、董事及高级管理人员 增持公司股份计划实施完毕暨增持结果公告 基于对公司未来发展前景的信心及长期投资价值的认可，同时为了进一步增 强投资者信心，维护公司及全体股东的利益，促进公司持续、稳定、健康发展， 公司控股股东兼董事长、总经理肖志华先生以及董事、首席财务官（财务总监）、 副总经理倪亮萍女士计划自 2024 年 1 月 31 日起 12 个月内，以其自有资金或自 筹资金通过上海证券交易所系统集中竞价交易方式增持公司股份，合计增持股份 金额不低于人民币 600 万元。具体内容详见公司于 2024 年 1 月 31 日刊载于上海 证券交易所网站的《关于控股股东兼董事长、董事及高级管理人员增持公司股份 计划的公告》。 2025 年 1 月 16 日，公司收到肖志华先生、倪亮萍女士发来的《关于股份增 持计划延期告知函》，在增持计划实施期间，因定期报告、临时公告敏感期及筹 划重大资产重组事项申请停牌等多种因素影响，能够实施股份增持的有效时间大 幅缩短，本次股份增持计划无法在原定期限内完成。同时，基 ...

FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 上海市方达律师事务所 关于控股股东增持上海奥浦迈生物科技股份有限公司股份的 法律意见书 致：上海奥浦迈生物科技股份有限公司 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法 律执业资格的律师事务所。本所受上海奥浦迈生物科技股份有限公司（以下简称 "奥浦迈"或"公司"）的委托，就奥浦迈控股股东肖志华先生（以下简称"增 持人"）自2024年1月31日至2025年5月31日期间内（以下简称"本次增持期间"） 通过上海证券交易所交易系统以集中竞价交易方式增持奥浦迈股份（以下简称 "本次增持"）符合免于 ...

3、分配方案： 本次利润分配以方案实施前的公司总股本113,548,754股为基数，向全体股东每股派发现金红利0.20000 元（含税），共计派发现金红利22,709,750.80元（含税）。 除公司自行发放对象外，无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股权 登记日上海证券交易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办理 指定交易的投资者可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易的股东红利暂 由中国结算上海分公司保管，待办理指定交易后再进行派发。 2、自行发放对象 公司股东肖志华、国寿成达（上海）健康产业股权投资中心（有限合伙）、常州稳实企业管理咨询合伙 企业（有限合伙）、宁波梅山保税港区铧杰股权投资管理有限公司－华杰（天津）医疗投资合伙企业 （有限合伙）、北京磐茂投资管理有限公司－磐信（上海）投资中心（有限合伙）的现金红利由公司自 行派发。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.20000元 本次利润分配方案 ...

Core Points - The company announced a cash dividend distribution of CNY 0.20000 per share, totaling CNY 22,709,750.80 for the fiscal year 2024 [1] - The dividend distribution plan was approved at the annual shareholders' meeting held on May 9, 2025 [1] - The record date for shareholders to receive the dividend is specified, along with the ex-dividend date and the payment date [1] Dividend Distribution Details - The total number of shares for the dividend calculation is 113,548,754 [1] - Cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited, Shanghai Branch [1] - Shareholders who have not completed designated trading will have their dividends held by the clearing company until the trading is completed [1] Taxation Information - Individual shareholders holding shares for over one year will not be subject to personal income tax on the dividend [3] - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated upon transfer of shares [3] - The effective tax burden for shares held for less than one month is 20%, while for shares held between one month and one year, it is reduced to 10% [3][5] Special Cases for Different Shareholders - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net dividend of CNY 0.18000 per share [5] - For Hong Kong Stock Exchange investors holding shares via the Shanghai-Hong Kong Stock Connect, the same 10% withholding tax applies, leading to a net dividend of CNY 0.18000 per share [5] - Other corporate shareholders will be responsible for their own tax declarations, receiving a gross dividend of CNY 0.20000 per share [6]

证券代码：688293 证券简称：奥浦迈 公告编号：2025-041 上海奥浦迈生物科技股份有限公司2024年年度 权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/5/22 | 2025/5/23 | 2025/5/23 | 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 9 日的2024年年度股东大会审议通过。 二、分配方案 1、发放年度：2024年年度 2、分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3、分配方案： 本次利润分配以方案实施前的公司总股本113,548,754股为基数，向全体股东 每股派发现金红利0.20000元（含税），共计派发现金红利22,709,750.80元（含税）。 是否涉及差异化分红送转：否 每股分配比例 每 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开发行股票募集资金按照相关 法律法规、规范性文件的规定在商业银行开立了募集资金专用账户。近日，公司部分募集资金专用账户 的注销手续已经办理完成，现将相关情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会于2022年6月13日出具的《关于同意上海奥浦迈生物科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2022〕1232号），并经上海证券交易所同意，公司首次公开 发行人民币普通股2,049.5082万股，每股面值为人民币1元，发行价格为每股人民币80.20元，募集资金 总额为人民币1,643,705,576.40元，扣除发行费用后实际募集资金净额为人民币1,510,944,779.75元。立信 会计师事务所（特殊普通合伙）于2022年8月30日出具了《验资报告》（信会师报字[2022]第ZA15717 号），验证募集资金已全部到位。 二、募集资金专户存放及专户管理情况 证券代码：6882 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-040 上海奥浦迈生物科技股份有限公司 关于部分募集资金专户销户完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次 公开发行股票募集资金按照相关法律法规、规范性文件的规定在商业银行开立了 募集资金专用账户。近日，公司部分募集资金专用账户的注销手续已经办理完成， 现将相关情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会于2022年6月13日出具的《关于同意上海奥浦 迈生物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕1232 号），并经上海证券交易所同意，公司首次公开发行人民币普通股2,049.5082万 股，每股面值为人民币1元，发行价格为每股人民币80.20元，募集资金总额为人 民 币 1,643,705,576.40 元 ， 扣 除 发 行 费 用 后 实 际 募 集 资 金 净 额 为 人 民 币 1,510,944,779.75元。立信会计师事 ...

Investment Rating - The report does not provide specific investment ratings for the sub-industries within the pharmaceutical sector [3]. Core Insights - The life sciences upstream sector has experienced a significant recovery since September 24, 2024, with a 60% increase in the index, outperforming the pharmaceutical and biotechnology sectors by 40 percentage points [4][23]. - The sector is currently in a rebound phase after undergoing a clearing phase from mid-2022 to late 2024, characterized by supply-demand imbalances and subsequent recovery [20][23]. Supply Side Summary - The supply side is witnessing a turning point, with local products continuously upgrading to mid-to-high-end levels, aiming for global leadership [5]. - The overall capital expenditure depreciation has dropped to its lowest level in nearly six years, indicating a recovery in the supply chain [29]. - Companies are experiencing a gradual recovery in gross profit margins, with some, like Aladdin and Nanmo Biology, showing signs of improvement after hitting lows [34]. Demand Side Summary - Research institutions and large pharmaceutical companies are steadily increasing their R&D expenditures, with improved financing potentially stimulating high growth in smaller pharmaceutical companies [6]. - The recognition of domestic brands is increasing, accelerating the process of replacing foreign products, particularly in protein and culture media categories [6]. Related Companies - **Aopumai**: A leading domestic brand in culture media, with a comprehensive layout in "culture media + CRO + CDMO" [8]. - **Aladdin**: A domestic high-end research reagent brand, expected to contribute additional growth from overseas [8]. - **Baipusais**: A leading domestic player in recombinant proteins, with a turning point in performance [8]. - **Nuowei Zhan**: A leader in molecular biological reagents, benefiting from the domestic replacement trend [8]. - **Jian Kai Technology**: A leading domestic PEG company, with new product releases expected to open up growth space [8]. - **BGI Genomics**: Focused on domestic markets while expanding globally, optimistic about accelerating domestic replacements [8].

Group 1 - Shanghai Jingfeng Mingyuan Semiconductor Co., Ltd. and Wuhan Changying Tongguang Technology Co., Ltd. have received shareholder approval for their asset purchase proposals, marking a significant step in their merger and acquisition processes [1] - Since the release of the "Eight Measures for Deepening the Reform of the Sci-Tech Innovation Board," the number of M&A transactions on the Sci-Tech Innovation Board has reached 100, indicating increased market activity and supporting high-quality development for listed companies [1] - The total disclosed transaction amount for these 100 M&A deals exceeds 24.7 billion yuan, with 39 new M&A transactions disclosed this year alone [1] Group 2 - Companies are utilizing various funding methods such as private placements, directed convertible bonds, and bank loans to enhance capital efficiency for acquisitions [2] - The 100 M&A transactions are primarily industrial mergers, focusing on companies within the same industry or related upstream and downstream sectors, which helps enhance product offerings and expand customer bases [2] - For instance, Xidi Microelectronics Group plans to acquire 100% of Shenzhen Chengxin Micro Technology Co., Ltd. to fill technology gaps in the AC-DC chip sector [2] Group 3 - Sci-Tech Innovation Board companies are also acquiring overseas mature enterprises to enhance international presence, with 15 overseas acquisition deals disclosed since the "Eight Measures" [3] - Acquisitions of unprofitable companies are aimed at strengthening supply chains, with 27 such deals reported since the "Eight Measures," including Shanghai Silicon Industry Group's acquisition of stakes in its subsidiaries to control the 300mm silicon wafer supply chain [3]